PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Cambridge Healthtech Institute

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

CHI Releases Final Agenda for the 4th Annual Immunogenicity Summit 2012 - World Leaders to Convene on October 10-12, Bethesda, MD - /
CHI Releases Final Agenda for the 4th Annual Immunogenicity Summit 2012


NewswireToday - /newswire/ - Needham, MA, United States, 2012/08/20 - World Leaders to Convene on October 10-12, Bethesda, MD - /

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Cambridge Healthtech Institute (CHI) has just released the final agenda for its 4th annual Immunogenicity Summit to be held October 10-12, 2012 at the DoubleTree by Hilton Hotel in Bethesda, MD. The event has grown to great heights with over 250 delegates in attendance last year representing over 50 organizations connecting industry, academia, and regulators on immunogenicity testing, immunogenicity avoidance, and regulatory guidance.

“Recent research for the Immunogenicity Summit 2012 revealed an increasing concern about immunogenicity as more innovator and biosimilar products approach the clinic. Current concerns and interests include hypersensitivity and immune complexes, the design of the clinical program, and regulatory authority requirements, particularly the implications of the new biosimilar guidance. There is an increasing interest in predictive tools to support clinical risk assessment. Immunogenicity mitigation is gaining momentum with investigators endeavoring to identify product characteristics that contribute to immunogenicity with a view to engineering and/or selecting non-immunogenic products. Novel tolerance induction approaches are also being investigated,” said Nicole Lyscom, Ph.D., Conference Director, CHI.

This year’s program features a 2-part format covering developments in assay technologies, risk assessment, regulatory guidance and means of predicting and avoiding immunogenicity.

Part One: Immunogenicity Assessment and Clinical Relevance (October 10-11)
Topics covered include: challenges of immunogenicity assays, detection of immune complexes, clinical relevance of anti-drug antibodies, clinical immunogenicity testing strategies, and biosimilars. Part One of the summit highlights three keynote & featured presentations. The first,“Detection of Immune Complex Formation in Non-Clinical Studies and Implications for Clinical Risk Assessment,” will be given by Steve J. Swanson, Ph.D. of Amgen, Inc. The featured presenters are Paul Chamberlain, NDA Advisory Board and Daniela Verthelyi, M.D., Ph.D., Chief, Immunology, Therapeutic Proteins, CDER/FDA.

Part Two: Immunogenicity Prediction and Mitigation (October 11-12)
Part Two begins with a Joint Plenary Session which presents regulatory guidance from the FDA together with a panel discussion, and a background to causes and avoidance of immunogenicity. The keynote presentation titled “Immune Tolerance Induction: Novel Approaches for Novel Clinical Indications” will be delivered by Amy S. Rosenberg, M.D., Director, Division of Therapeutic Proteins, CDER/FDA followed by featured presenters Valerie Quarmby, Ph.D., Director and Principal Scientist, BioAnalytical Sciences, Genentech, Inc., and Jack Ragheb, M.D., Ph.D., Principal Investigator, Immunology, Therapeutic Proteins, CDER/FDA. Other topics covered include: factors contributing to immunogenicity, predictive methods for immunogenicity, and immune tolerance approaches /reducing immunogenicity.

Plus, delegates may attend three pre-conference short courses on binding and neutralizing assays and risk assessment, breakout discussions, networking functions, and an exhibit/poster hall. Delegates attending the Immunogenicity Summit 2012 may track-hop to the sessions at CHI’s concurrent event, PK/PD of Novel Contructs: Bispecific Antibodies, Antibody Fragments, and ADCs.

Complete event details are on-line at

To inquire about sponsoring and/or exhibiting, contact Tim McLucas, 781-972-1342, tmclucas[.]
Writers and editors are encouraged to attend. To request a press pass, contact Lisa Scimemi at lscimemi[.]

About Cambridge Healthtech Institute

CHI ( is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Barnett Educational Services, Cambridge Meeting Planners and CHI’s Media Group, which includes news websites and e-newsletters including Bio-IT World and eCliniqua. Founded in 1992, CHI strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Cambridge Healthtech Institute


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

CHI Releases Final Agenda for the 4th Annual Immunogenicity Summit 2012

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: James Prudhomme - 
781-972-5400 jprudhomme[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Cambridge Healthtech Institute securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Cambridge Healthtech Institute / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Deb Sheppard - Medium Psychic Author Speaker

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (